Celera's Q4 Revenues Increase 15 Percent; Swings to Loss | GenomeWeb

NEW YORK (GenomeWeb News) – Celera reported after the close of the market on Tuesday that its fourth-quarter revenues rose 15 percent year over year, while the firm swung from a profit to a loss on increased SG&A spending.

The Alameda, Calif.-based personalized disease management products firm brought in revenues of $47.3 million for the three-month period ended Dec. 27, compared to revenue of $40.3 million for the three-month period ended Dec. 31, 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.